JiangXi Tianxin Pharmaceutical Co., Ltd. Class A

JiangXi Tianxin Pharmaceutical Co., Ltd. Class A

SSSE:603235
23.53
CNY
-0.14
(-0.59%)
1.27EPS
20.45P/E
11.36BMarket Cap
JiangXi Tianxin Pharmaceutical Co., Ltd. Class A
SSE:603235
(Shanghai Stock Exchange)

Recent

price

23.53

P/E

ratio

20.45

div

yld

2.43%

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
7.26
5.15
5.84
6.41
5.59
4.31
5.05
5.35
5.94
Revenue per Share
3.09
1.85
2.25
1.89
1.51
1.09
1.49
1.35
1.27
Basic EPS, GAAP
2.83
1.86
2.18
1.53
0.84
0.44
-1.3
0.11
- -
Free Cash Flow per Basic Share
2.49
2.4
2.16
2.23
0.02
0.72
0.5
0.7
0.57
Dividend per Share
3.48
3.35
2.93
4.84
9.27
9.67
10.54
11.23
11.64
Book Value per Share
3.31
3.18
2.75
4.56
9.02
9.23
10.11
10.8
11.22
Tangible Book Value per Share
355
393
394
394
412
437
437
438
434
Basic Weighted Avg Shares
2,578
2,025
2,304
2,522
2,305
1,882
2,209
2,345
2,579
Sales/Revenue/Turnover
48.23
40.84
49.14
36.76
27.12
24.81
30.23
29.4
26.43
Operating Margin (%)
60
73
89
110
127
139
154
190
- -
Depreciation Expense
1,098
728
887
744
622
476
651
592
552
Net Income, GAAP
16.58
15.05
15.25
14.83
14.28
15.8
15.62
16.02
15.85
Effective Tax Rate (%)
42.59
35.94
38.51
29.49
26.99
25.28
29.49
25.23
21.38
Profit Margin (%)
597
432
156
902
2,855
2,660
2,186
2,147
2,044
Working Capital
50
45
46
34
5
5
119
313
105
LT Debt
1,372
1,322
1,155
1,909
4,058
4,233
4,616
4,917
5,097
Total Equity
- -
42.27
56.38
39.12
19.58
11.24
14.3
11.71
10.27
Return on Invested Capital (%)
- -
44.45
57.03
40.07
19.85
11.36
14.35
11.74
10.34
Return on Capital (%)
- -
54.03
71.64
48.56
20.85
11.48
14.72
12.41
11.28
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
93
211
444
LT Borrowings
313
273
93
LT Finance Leases
13
13
12
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
438
438
438
Market Capitalization
11,597
9,741
11,365

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,793
3,024
2,997
Cash, Cash Equivalents & STI
1,568
1,808
1,755
Accounts Receivable, Net
313
305
282
Inventories
542
685
732
Total Current Liabilities
550
850
953
Payables & Accruals
- -
- -
- -
ST Debt
93
211
444
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
39.55%
6.51%
Free Cash Flow
- -
-123.64%
-108.58%
Net Income, GAAP
- -
-5.67%
-9.16%
Sales/Revenue/Turnover
- -
1.21%
6.18%
Total Cash Common Dividend
- -
877.9%
38.43%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
494
572
547
595
2,209
2025
619
503
- -
714
2,345
2026
640
670
556
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.34
0.45
0.34
0.36
1.49
2025
0.5
0.32
- -
0.3
1.35
2026
0.34
0.4
0.23
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.47
0.03
- -
0.5
2025
- -
0.64
- -
0.01
0.7
2026
0.01
0.11
0.45
- -
- -
Business
Jiangxi Tianxin Pharmaceutical Co., Ltd. is a China-based pharmaceutical and specialty chemical company primarily engaged in the research, development, production, and global commercialization of active pharmaceutical ingredients, fine chemical intermediates, and nutritional feed and food additives. Founded in 2004 and headquartered in Jingdezhen, Jiangxi Province, the company operates across the human health, animal nutrition, pharmaceutical synthesis, food and beverage, and personal care sectors. Its core product portfolio comprises B-complex vitamins, including vitamin B1 (thiamine hydrochloride and thiamine mononitrate), vitamin B6 (pyridoxine hydrochloride), vitamin B5 (D-calcium pantothenate), vitamin B9 (folic acid), vitamin B3 (nicotinamide and niacin), and biotin; fat-soluble and specialty nutritional ingredients, including vitamin D3 and ascorbyl palmitate; high-potency functional compounds, including coenzyme Q10; and customized chemical intermediates and formulation-grade raw materials used in commercial feed premixes, dietary supplements, and therapeutic formulations. Jiangxi Tianxin Pharmaceutical operates advanced manufacturing complexes in Jiangxi and Ningxia, distributing products domestically throughout China and exporting globally across Europe, North America, South America, and the Asia-Pacific region. In recent major operational developments, the company has expanded its manufacturing footprint through the ongoing build-out and scale-up of its Ningxia production facility via its subsidiary Ningxia Tianxin Pharmaceutical Co., Ltd., strengthening upstream raw material integration and securing key intermediate supplies; accelerated product line diversification into high-value functional nutrition assets, including dedicated capacity expansions for coenzyme Q10 and vitamin D3 derivatives; deployed advanced green synthesis and intelligent process automation across its production lines to reduce energy consumption and optimize operating costs; and expanded its international regulatory compliance portfolio with global health and food safety certifications to drive further penetration in overseas pharmaceutical and nutritional markets.